The concept of ‘best-fit vendor’ is broken. It relies on surface signals: how polished their pitch is, how available they seem, whether you’ve heard of them. The truth is, fit is not a feeling. Fit is evidence. Sponsors should evaluate vendors on operational proof: how they handle constraints, what their staffing model actually looks like, whether their proposal is internally consistent, how they respond to contradictions. The vendors that succeed are not the ones that feel like the best fit. They’re the ones that demonstrate the discipline to deliver exactly what you’ve defined, on time, with the governance you need.
KEY TAKEAWAYS
Key Takeaways
- Best-fit vendor selection relies on surface signals (reputation, polish, availability) that don’t predict execution.
- Operational proof, how a vendor handles constraints, staff continuity, and contradictions, is a more reliable indicator of success.
- Governance-led vendor evaluation shifts focus from cultural fit to execution alignment and decision-making clarity.
- Vendors that can articulate their constraints and staffing model are more trustworthy than vendors that promise everything.
- The best vendor for your project is the one whose operational model aligns with how you govern and make decisions.
Here’s what most vendors know: Clinical sponsors are looking for vendors that feel right. Polished. Available. Responsive. So vendors optimize for that. They build great decks. They make themselves available for endless discovery calls. They promise flexibility and adaptability.
Understanding the Fundamentals
And then execution starts. The resource that was going to lead your project gets pulled onto something else. The timeline they approved starts shifting because no one was clear on what ‘done’ looked like. The governance structure you agreed to in kickoff never quite takes shape because no one defined what the sponsor’s decision rights actually are.
The problem wasn’t the vendor. The problem was that you were evaluating fit based on signals that don’t matter.
The Real Cost of Misalignment
Operational proof is different. It’s asking: How does this vendor actually work? What are their real constraints? How do they staff projects? What happens when we ask them something that contradicts something else in their proposal?
Let me be clear. The vendors that fail in clinical development aren’t failing because they lack capability. They’re failing because there’s misalignment between what the sponsor needs and what the vendor can realistically deliver. That misalignment is visible in the proposal and in how they respond to constraints. Most sponsors just don’t know how to read it.
Building Governance Infrastructure
At Seuss+, the work is helping sponsors see the governance signals in vendor proposals. A vendor that can clearly articulate their staffing model is more trustworthy than a vendor that promises unlimited flexibility. A vendor that tells you their constraints is more reliable than a vendor that says they can do anything. A vendor whose proposal is internally consistent is more aligned with your needs than a vendor whose proposal shifts depending on the conversation.
This is governance-led vendor evaluation. You’re not asking, “Do we like working with them?” You’re asking, “Is their operational model aligned with how we govern? Can we clearly define what they’re supposed to deliver? Can we hold them accountable for it?”
The Speed Advantage
The vendors that succeed in clinical development are the ones where there’s no surprises in the governance structure. You ask them about their decision cadence, and it matches what you need. You ask them how they handle scope change, and their answer aligns with your change management process. You ask them about continuity, and their staffing model supports it.
Kieran Engels has worked with dozens of sponsors who hired vendors based on best-fit feeling and then spent months in rework and negotiation. Every single time, the signs were in the proposal. The vendor was promising something that contradicted something else. Or they were being vague about staffing. Or their timeline assumed a decision-making pace that didn’t match how the sponsor actually operates.
The other vendors, the ones that deliver on time and on scope, are usually not the most impressive in the pitch room. They’re the ones who asked the most questions about your governance. They’re the ones who said no to things that didn’t fit their model. They’re the ones who were explicit about their constraints.
This is also why vendor failure isn’t really vendor failure. It’s governance failure. If you hired a vendor based on a feeling rather than operational alignment, and they fail to deliver, that’s not because they’re incapable. It’s because you didn’t diagnose what they could actually deliver before you signed.
Governance-led vendor evaluation prevents that. It forces both sponsor and vendor to get clarity on expectations before execution. It creates accountability because the expectations are explicit. And it prevents the months of misalignment and rework that come from discovering too late that the vendor’s operational model doesn’t match your governance needs.
Traditional Vendor Selection Criteria vs. Governance-Led Criteria
| Selection Dimension | Traditional Best-Fit Approach | Governance-Led Approach |
| Decision-making | They seem responsive and flexible | Can they articulate your approval cadence? Do they have the same decision rights you do? |
| Staffing and continuity | They said they have good people | What’s their actual staffing model? How do they backfill? What’s the continuity guarantee? |
| Timeline management | Their proposal timeline feels reasonable | Does their timeline assume a decision-making pace that matches your governance? Are assumptions explicit? |
| Change management | They said they’re adaptable to change | How do they handle scope change? Does their change process align with yours? Who approves changes? |
| Accountability | Trust that they’ll deliver if we have a good relationship | Clear KPIs, reporting cadence, escalation path, and performance expectations defined upfront. |
| Internal consistency | Not really evaluated | Does their proposal contradict itself? Do different team members say different things? That’s your signal. |
| Constraint articulation | We assume they can do anything | What can’t they do? When would they say no? Vendors that articulate constraints are more trustworthy. |
Vendors that succeed aren't the ones that feel like the best fit. They're the ones that can prove their operational model aligns with how you govern, make decisions, and hold people accountable.
Key Industry Data
Daily trial delays cost sponsors between $600,000 and $8 million per day in lost revenue opportunity. (Source: Tufts CSDD)
63% of all new trial starts now come from emerging biotech companies, up from 56% in 2019. (Source: IQVIA)
The top five CRO companies hold more than 35% of total market share. (Source: IQVIA)
Between 50% and 60% of all clinical trial activities are now outsourced to CROs globally. (Source: IQVIA)
The global CRO market reached $79.5 billion in 2023 and is projected to exceed $125 billion by 2030. (Source: Grand View Research)
Frequently Asked Questions
Ask them the same question twice, from different angles. Ask them about their staffing model, then ask them about continuity. See if the answers align. Ask them about their decision-making process, then ask them how they handle change. Inconsistency is a signal. The vendors that succeed are the ones whose answers are the same no matter how you frame the question.
Look for vagueness about staffing, timeline, or decision-making. Look for contradictions between different sections. Look for assumptions about your process that you haven’t confirmed. Look for promises of unlimited flexibility. These aren’t vendor problems. They’re signals that you haven’t gotten clarity on governance yet.
No. It actually shortens the entire timeline. Yes, the evaluation takes more rigor upfront. But you avoid months of misalignment and rework downstream. The sponsors who move fastest are the ones who got clear on governance before they signed the contract.
If a vendor pushes back on your governance questions, that’s your signal. The vendors that succeed are the ones that welcome clarity and constraints. They know that explicit expectations are easier to meet than vague ones. Pushback usually means the vendor is uncomfortable with the level of accountability you’re asking for.
This approach works better for new vendors. Established vendors often rely on reputation and historical relationships. New vendors have to earn trust through operational clarity and performance. Governance-led evaluation levels the playing field and forces all vendors to prove alignment, not just reputation.
About the Author
Kieran Engels is CEO and Co-Founder of Seuss+, a strategy and execution partner helping biotech sponsors optimize vendor relationships across clinical development. With more than a decade of experience in vendor governance, risk management, and clinical trial execution, Kieran works with biotech leadership teams to build the oversight systems that protect timelines, budgets, and data integrity. Learn more at seuss.plus.
